Are you Dr. Daniel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 87 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
605 Glenwood Dr
Suite 200
Chattanooga, TN 37404Phone+1 423-698-1844Fax+1 423-624-2226
Summary
- Dr. Brooke Daniel, MD is an oncologist in Chattanooga, Tennessee. She is currently licensed to practice medicine in Tennessee, Florida, and Georgia. She is affiliated with CHI Memorial and Parkridge Medical Center.
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1998 - 2001
University of Tennessee Health Science Center College of MedicineClass of 1998
Certifications & Licensure
FL State Medical License 2020 - Present
GA State Medical License 2005 - 2025
TN State Medical License 2005 - 2025
VA State Medical License 1998 - 2006
NC State Medical License 2002 - 2005- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Clinical Trials
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer.Marcie Beasley, Brooke Daniel
Journal of the Advanced Practitioner in Oncology. 2023-04-01 - 5 citationsPhase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapyDenise A. Yardley, N. W. Peacock, Brooke R. Daniel, Betrand Anz, David C. Molthrop
Breast Cancer Research and Treatment. 2020-02-14 - 17 citationsTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancerDenise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky
Breast Cancer Research and Treatment. 2017-05-15
Press Mentions
Champions of Health Care 2024: CHI Memorial HospitalSeptember 1st, 2024- OneOncology Names Dr. Davey Daniel as Chief Medical OfficerFebruary 7th, 2022
